MX2021015445A - Ensayo de quimioluminiscencia a base de oxidasa de leucocitos fagocitica en sangre entera y en fluidos corporales aplicables a las pruebas de diagnostico de punto de cuidado (poc) la medicion de punto de cuidado (poc) de la funcion neutrofila absoluta (anf). - Google Patents

Ensayo de quimioluminiscencia a base de oxidasa de leucocitos fagocitica en sangre entera y en fluidos corporales aplicables a las pruebas de diagnostico de punto de cuidado (poc) la medicion de punto de cuidado (poc) de la funcion neutrofila absoluta (anf).

Info

Publication number
MX2021015445A
MX2021015445A MX2021015445A MX2021015445A MX2021015445A MX 2021015445 A MX2021015445 A MX 2021015445A MX 2021015445 A MX2021015445 A MX 2021015445A MX 2021015445 A MX2021015445 A MX 2021015445A MX 2021015445 A MX2021015445 A MX 2021015445A
Authority
MX
Mexico
Prior art keywords
poc
care
phagocytes
point
anf
Prior art date
Application number
MX2021015445A
Other languages
English (en)
Inventor
Jr Jackson T Stephens
Robert C Allen
John C Allen
Original Assignee
Binary Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Binary Llc filed Critical Binary Llc
Publication of MX2021015445A publication Critical patent/MX2021015445A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/03—Oxidoreductases acting on NADH or NADPH (1.6) with oxygen as acceptor (1.6.3)
    • C12Y106/03001—NAD(P)H oxidase (1.6.3.1), i.e. NOX1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Ecology (AREA)
  • Plasma & Fusion (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Un método para estimar un número de fagocitos en un fluido corporal de un animal, incluye estimular la actividad de oxidasa NADPH de los fagocitos; y cuantificar una desoxigenación reductora resultante de un sustrato quimioluminigénico mediante una quimioluminiscencia emitida del sustrato quimioluminigénico con el uso de un instrumento con capacidad de medir luz. La actividad de NADPH oxidasa fagocítica es estimulada preferiblemente por un agente inmunológico o químico con capacidad de activar un estallido respiratorio por los fagocitos, por un estímulo en solución o se recubre sobre una superficie contactada por los fagocitos. El estímulo preferiblemente es forbol miristato acetato (PMA). El animal preferiblemente es un ser humano y el fluido corporal es preferiblemente sangre y/o líquido cefalorraquídeo. Los fagocitos preferiblemente son leucocitos neutrófilos y el sustrato quimioluminigénico es preferiblemente lucigenina (dinitrato de N,N'-dimetil-9,9'-biacrid inio). También se proporciona un método de tratamiento basado en el método de estimación.
MX2021015445A 2019-06-27 2020-06-10 Ensayo de quimioluminiscencia a base de oxidasa de leucocitos fagocitica en sangre entera y en fluidos corporales aplicables a las pruebas de diagnostico de punto de cuidado (poc) la medicion de punto de cuidado (poc) de la funcion neutrofila absoluta (anf). MX2021015445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867348P 2019-06-27 2019-06-27
PCT/US2020/036998 WO2020263571A1 (en) 2019-06-27 2020-06-10 Oxidase-based chemiluminescence assay of phagocytic leukocytes in whole blood and body fluids applicable to point-of-care (poc) diagnostic testing point-of-care (poc) measurement of absolute neutrophil function (anf)

Publications (1)

Publication Number Publication Date
MX2021015445A true MX2021015445A (es) 2022-04-06

Family

ID=74060696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015445A MX2021015445A (es) 2019-06-27 2020-06-10 Ensayo de quimioluminiscencia a base de oxidasa de leucocitos fagocitica en sangre entera y en fluidos corporales aplicables a las pruebas de diagnostico de punto de cuidado (poc) la medicion de punto de cuidado (poc) de la funcion neutrofila absoluta (anf).

Country Status (10)

Country Link
US (1) US20220308046A1 (es)
EP (1) EP3990900A4 (es)
JP (1) JP2022540349A (es)
KR (1) KR20220041047A (es)
CN (1) CN114391095A (es)
AU (1) AU2020304536A1 (es)
CA (1) CA3143956A1 (es)
IL (1) IL289193A (es)
MX (1) MX2021015445A (es)
WO (1) WO2020263571A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023554149A (ja) * 2020-12-22 2023-12-26 セロクソ リミテッド 敗血症を診断およびモニターする方法
WO2022167784A1 (en) * 2021-02-02 2022-08-11 Seroxo Limited Monitoring covid-19 progression and treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATA901588A (de) * 1987-11-19 1994-07-15 Sandoz Ag Von humanmonozyten abgeleiteter neutrophilenaktivierungsfaktor (naf) und verfahren zu seiner herstellung
US5108899A (en) * 1989-10-31 1992-04-28 Exoxemis, Inc. Chemiluminescence assay of in vivo inflammation
ES2151902T3 (es) * 1992-03-10 2001-01-16 Quidel Corp Medio de separacion de globulos rojos para dosificarlos mediante union especifica.
GB0225885D0 (en) 2002-11-06 2002-12-11 Isis Innovation Quantifying exposure to stress
EP2412818A1 (en) * 2010-07-26 2012-02-01 Assistance Publique Hôpitaux De Paris Diagnosis of bacterial meningitis based on the measure of ROS production in a sample of cerebrospinal fluid
GB2494653A (en) * 2011-09-13 2013-03-20 Orreco Ltd Apparatus for blood analysis
GB201616640D0 (en) 2016-09-30 2016-11-16 Sarphie David And Mian Rubina Monitoring cancer recurrence and progression

Also Published As

Publication number Publication date
JP2022540349A (ja) 2022-09-15
CN114391095A (zh) 2022-04-22
IL289193A (en) 2022-02-01
CA3143956A1 (en) 2020-12-30
AU2020304536A1 (en) 2022-01-06
EP3990900A4 (en) 2023-07-26
EP3990900A1 (en) 2022-05-04
KR20220041047A (ko) 2022-03-31
WO2020263571A1 (en) 2020-12-30
US20220308046A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
Kestenbaum et al. Impaired skeletal muscle mitochondrial bioenergetics and physical performance in chronic kidney disease
MX2021015445A (es) Ensayo de quimioluminiscencia a base de oxidasa de leucocitos fagocitica en sangre entera y en fluidos corporales aplicables a las pruebas de diagnostico de punto de cuidado (poc) la medicion de punto de cuidado (poc) de la funcion neutrofila absoluta (anf).
EP1545296B1 (en) Calibration technique for non-invasive medical devices
ATE423217T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
WO2008132464A3 (en) Mek5 and related proteins as biomarkers of neurodegenerative diseases
CN104704361B (zh) 线粒体毒性检测
Epstein et al. Bedside assessment of tissue oxygen saturation monitoring in critically ill adults: an integrative review of the literature
ATE441107T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von kírperflüssigkeiten
ATE418909T1 (de) Medizinischer sensor
Dunaev Wearable devices for multimodal optical diagnostics of microcirculatory-tissue systems: application experience in the clinic and space
Goldberg et al. Brain tissue pH and ventilatory acclimatization to high altitude
Wieland et al. Systematic changes in levels of physiological activity during a four‐month period
Kenny et al. The feasibility of a novel index from a wireless Doppler ultrasound patch to detect decreasing cardiac output in healthy volunteers
EP3387986A1 (en) Method for determining water deficiency in a person's body
RU2728262C1 (ru) Способ определения энергозатрат организма человека
Navarro et al. Cerebrospinal fluid cyclic guanosine 3′ 5′ monophosphate levels in Parkinson's disease
Safer et al. Could single-slice quantitative computerized tomography image analysis at the midpoint of the third lumbar region accurately predict total body skeletal muscle
RU2505952C1 (ru) Способ определения степени индивидуальной устойчивости к декомпрессионной болезни мужчин-водолазов в возрасте 20-30 лет
JPWO2008108440A1 (ja) 哺乳動物用ストレス測定方法とその測定具
RU2299004C2 (ru) Способ диагностики синдрома вегетативной дистонии токсического генеза от воздействия комплекса химических веществ
Wegerich et al. An in vitro laboratory investigation on layer thickness-independent prediction of the hemoglobin concentration
Baines et al. Comparison of venous, capillary and interstitial blood glucose data measured during hyperbaric oxygen treatment from patients with diabetes mellitus
Bailey et al. Severe hypoxaemic hypercapnia compounds cerebral oxidative–nitrosative stress during extreme apnoea: Implications for cerebral bioenergetic function
Rajalakshmi et al. Comparison of cardiovascular parameters and cardiac autonomic activity of obese and normal weight school children in Puducherry
Bader et al. Biochemical status of soft tissues subjected to sustained pressure